Case number 1:23-cv-00554
Genzyme Corporation et al v. Novartis Gene Therapies, Inc. et al > Documents
| Date Field | Doc. No. | Description (Pages) |
|---|---|---|
| Feb 14, 2024 | 65 | Report to the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 10,429,288. (Attachments: # 1 Order)(nms) (Entered: 02/14/2024) (0) |
| Feb 14, 2024 | 64 | SO ORDERED Granting 63 Joint Stipulation and Order of Dismissal with Prejudice (***Civil Case Terminated). Signed by Judge Richard G. Andrews on 2/14/2024. (nms) (Entered: 02/14/2024) (3) |
| Feb 14, 2024 | 63 | STIPULATION of Dismissal with Prejudice, by Novartis Gene Therapies, Inc., Novartis Pharmaceuticals Corporation. (Joyce, Alexandra) Modified on 2/14/2024 (nms). (Entered: 02/14/2024) (3) |
| Feb 9, 2024 | 62 | REDACTED VERSION of 60 Letter by Novartis Gene Therapies, Inc., Novartis Pharmaceuticals Corporation. (Joyce, Alexandra) (Entered: 02/09/2024) (2) |
| Feb 2, 2024 | 61 | ORAL ORDER: The request for a temporary stay through and including February 15, 20234 (D.I. 60 ) is GRANTED. Ordered by Judge Richard G. Andrews on 2/2/2024. (nms) (Entered: 02/02/2024) (0) |
| Feb 2, 2024 | 60 | [SEALED] Joint Letter to The Honorable Richard G. Andrews, from the Parties, regarding request for temporary stay. (Joyce, Alexandra) Modified on 2/2/2024 (nms). (Entered: 02/02/2024) (0) |
| Jan 11, 2024 | 59 | ORAL ORDER: The request to continue the January 16, 2024, Markman (D.I. 58 ) is GRANTED. The parties are to file a joint status report due no later than 2/8/2024. Ordered by Judge Richard G. Andrews on 1/11/2024. (nms) (Entered: 01/11/2024) (0) |
| Jan 10, 2024 | 58 | Joint letter to Judge Andrews, from David E. Wilks, regarding Markman Hearing. (Wilks, David) Modified on 1/11/2024 (nms). (Entered: 01/10/2024) (1) |
| Dec 21, 2023 | 57 | SO ORDERED Granting 56 Joint Motion Requesting Claim Construction Hearing. Signed by Judge Richard G. Andrews on 12/21/2023. (nms) (Entered: 12/21/2023) (4) |
| Dec 20, 2023 | 56 | Joint Motion Requesting Claim Construction Hearing - filed by Aventis Inc., Genzyme Corporation. (Vavala, Donald) Modified on 12/21/2023 (nms). (Entered: 12/20/2023) (4) |
| Dec 20, 2023 | 55 | APPENDIX re 54 Joint Claim Construction Brief, by Aventis Inc., Genzyme Corporation. (Attachments: # 1 Exhibits 1-10)(Vavala, Donald) Modified on 12/21/2023 (nms). (Entered: 12/20/2023) (0) |
| Dec 20, 2023 | 54 | JOINT Claim Construction Brief, filed by Genzyme Corporation, Aventis Inc.. (Vavala, Donald) Modified on 12/21/2023 (nms). (Entered: 12/20/2023) (30) |
| Dec 15, 2023 | 53 | NOTICE OF SERVICE of Defendants' Sur-Reply Claim Construction Brief filed by Novartis Gene Therapies, Inc., Novartis Pharmaceuticals Corporation.(Joyce, Alexandra) (Entered: 12/15/2023) (3) |
| Dec 7, 2023 | 52 | NOTICE OF SERVICE of Plaintiffs Reply Claim Construction Brief filed by Aventis Inc., Genzyme Corporation.(Vavala, Donald) (Entered: 12/07/2023) (4) |
| Dec 6, 2023 | 51 | STIPULATION and [Proposed] Order Regarding the Exchange of Claim Construction Briefs by Aventis Inc., Genzyme Corporation. (Vavala, Donald) (Entered: 12/06/2023) (3) |
| Nov 22, 2023 | 50 | NOTICE OF SERVICE of Defendants' Answering Claim Construction Brief and Exhibits filed by Novartis Gene Therapies, Inc., Novartis Pharmaceuticals Corporation.(Joyce, Alexandra) (Entered: 11/22/2023) (3) |
| Nov 16, 2023 | 49 | NOTICE OF SERVICE of (1) Defendants' Responses and Objections to Plaintiffs' First Set of Interrogatories (Nos. 1-9), and (2) Defendants' Responses and Objections to Plaintiffs' First Set of Requests for Production of Documents and Things (Nos. 1-25) filed by Novartis Gene Therapies, Inc., Novartis Pharmaceuticals Corporation.(Joyce, Alexandra) (Entered: 11/16/2023) (3) |
| Nov 13, 2023 | 48 | NOTICE OF SERVICE of (1) Plaintiffs Objections and Responses to Defendants First Set of Requests for Production of Documents and Things Nos. 1-45 and (2) Plaintiffs Objections and Responses to Defendants First Set of Interrogatories Nos. 1-14 filed by Aventis Inc., Genzyme Corporation.(Vavala, Donald) (Entered: 11/13/2023) (4) |
| Nov 8, 2023 | 47 | NOTICE OF SERVICE of Plaintiffs Opening Claim Construction Brief filed by Aventis Inc., Genzyme Corporation.(Vavala, Donald) (Entered: 11/08/2023) (4) |
| Nov 7, 2023 | 46 | NOTICE OF SERVICE of Defendants' Initial Invalidity Contentions regarding U.S. Patent No. 10,429,288 and Appendix A filed by Novartis Gene Therapies, Inc., Novartis Pharmaceuticals Corporation.(Joyce, Alexandra) (Entered: 11/07/2023) (3) |
| Oct 18, 2023 | 45 | JOINT Claim Construction Chart, by Aventis Inc., Genzyme Corporation. (Attachments: # 1 Exhibit A, # 2 Exhibit B)(Wilks, David) Modified on 10/19/2023 (nms). (Entered: 10/18/2023) (0) |
| Oct 17, 2023 | 44 | NOTICE OF SERVICE of (1) Plaintiffs First Set of Interrogatories to Defendants and (2) Plaintiffs First Set of Requests for Production of Documents and Things filed by Aventis Inc., Genzyme Corporation.(Vavala, Donald) (Entered: 10/17/2023) (4) |
| Oct 13, 2023 | 43 | NOTICE OF SERVICE of (1) Novartis's First Set of Interrogatories to Plaintiffs (Nos. 1-14), and (2) Novartis's First Set of Requests for Production of Documents and Things (Nos. 1-45) filed by Novartis Gene Therapies, Inc., Novartis Pharmaceuticals Corporation.(Joyce, Alexandra) (Entered: 10/13/2023) (3) |
| Oct 6, 2023 | 42 | NOTICE OF SERVICE of Plaintiffs Initial Claim Charts on Infringement of the 288 Patent pursuant to Paragraph 4(C) of the Default Standard for Discovery filed by Aventis Inc., Genzyme Corporation.(Vavala, Donald) (Entered: 10/06/2023) (4) |
| Sep 27, 2023 | 41 | NOTICE OF SERVICE of Plaintiffs' Claim Construction Disclosure filed by Aventis Inc., Genzyme Corporation.(Vavala, Donald) (Entered: 09/27/2023) (4) |
| Sep 27, 2023 | 40 | NOTICE OF SERVICE of Defendants' Claim Construction Disclosure filed by Novartis Gene Therapies, Inc., Novartis Pharmaceuticals Corporation.(Joyce, Alexandra) (Entered: 09/27/2023) (3) |
| Sep 12, 2023 | 39 | NOTICE OF SERVICE of Core Technical Documents Pursuant to Paragraph 4(b) of the Delaware Default Standard of Discovery filed by Novartis Gene Therapies, Inc., Novartis Pharmaceuticals Corporation.(Joyce, Alexandra) (Entered: 09/12/2023) (3) |
| Aug 16, 2023 | 38 | NOTICE OF SERVICE of Initial Disclosures Pursuant to Paragraph 3 of the Default Standard for Discovery of ESI filed by Novartis Gene Therapies, Inc., Novartis Pharmaceuticals Corporation.(Joyce, Alexandra) (Entered: 08/16/2023) (3) |
| Aug 16, 2023 | 37 | NOTICE OF SERVICE of Plaintiffs Disclosures under Paragraph 3 of the Default Standard for Discovery filed by Aventis Inc., Genzyme Corporation.(Vavala, Donald) (Entered: 08/16/2023) (4) |
| Aug 11, 2023 | 36 | NOTICE OF SERVICE of Plaintiffs Disclosures under Paragraph 4(a) of the Default Standard for Discovery filed by Aventis Inc., Genzyme Corporation.(Vavala, Donald) (Entered: 08/11/2023) (4) |
| Jul 26, 2023 | 35 | SO ORDERED Granting 34 Stipulated Protective Order. Signed by Judge Richard G. Andrews on 7/26/2023. (nms) (Entered: 07/26/2023) (30) |
| Jul 25, 2023 | 34 | STIPULATION Protective Order by Aventis Inc., Genzyme Corporation. (Attachments: # 1 Exhibit A)(Czerwonka, Scott) (Entered: 07/25/2023) (0) |
| Jul 25, 2023 | N/A | SO ORDERED, re 33 STIPULATION and Proposed Order to Extend Time to submit a stipulated protective order to July 26, 2023. Signed by Judge Richard G. Andrews on 7/25/2023. (nms) (Entered: 07/25/2023) (0) |
| Jul 24, 2023 | 33 | STIPULATION and Proposed Order to Extend Time to submit a stipulated protective order to July 26, 2023 - filed by Novartis Gene Therapies, Inc., Novartis Pharmaceuticals Corporation. (Joyce, Alexandra) Modified on 7/25/2023 (nms). (Entered: 07/24/2023) (3) |
| Jul 21, 2023 | N/A | SO ORDERED, re 32 STIPULATION and Proposed Order to Extend Time to submit Stipulated Protective Order to July 24, 2023. Signed by Judge Richard G. Andrews on 7/21/2023. (nms) (Entered: 07/21/2023) (0) |
| Jul 20, 2023 | 32 | STIPULATION and Proposed Order to Extend Time to submit Stipulated Protective Order to July 24, 2023 - filed by Aventis Inc., Genzyme Corporation. (Czerwonka, Scott) Modified on 7/21/2023 (nms). (Entered: 07/20/2023) (3) |
| Jul 19, 2023 | N/A | SO ORDERED, re 31 MOTION for Pro Hac Vice Appearance of Attorney Aida Liman-Tinguiri and Christohper D. Weber, Ph.D., filed by Novartis Pharmaceuticals Corporation, Novartis Gene Therapies, Inc.. Signed by Judge Richard G. Andrews on 7/19/2023. (nms) (Entered: 07/19/2023) (0) |
| Jul 19, 2023 | 31 | MOTION for Pro Hac Vice Appearance of Attorney Aida Liman-Tinguiri and Christohper D. Weber, Ph.D. - filed by Novartis Gene Therapies, Inc., Novartis Pharmaceuticals Corporation. (Silver, Daniel) (Entered: 07/19/2023) (4) |
| Jul 17, 2023 | 29 | NOTICE OF SERVICE of Plaintiffs' Rule 26(a)(1) Initial Disclosures filed by Aventis Inc., Genzyme Corporation.(Wilks, David) (Entered: 07/17/2023) (4) |
| Jul 17, 2023 | 30 | NOTICE OF SERVICE of Defendants' Rule 26(a)(1)(A) Disclosures filed by Novartis Gene Therapies, Inc., Novartis Pharmaceuticals Corporation.(Joyce, Alexandra) (Entered: 07/17/2023) (3) |
| Jul 14, 2023 | N/A | Pro Hac Vice Attorneys Noah M. Leibowitz, Martin J. Black, Jonathan D.J. Loeb, and Daniel Roberts for Aventis Inc. and Genzyme Corporation added for electronic noticing. Pursuant to Local Rule 83.5 (d)., Delaware counsel shall be the registered users of CM/ECF and shall be required to file all papers. (mpb) (Entered: 07/14/2023) (0) |
| Jul 10, 2023 | N/A | ORAL ORDER: The Rule 16(b) Conference scheduled for 7/12/2023, is CANCELED. Ordered by Judge Richard G. Andrews on 7/10/2023. (nms) (Entered: 07/10/2023) (0) |
| Jul 10, 2023 | 28 | SCHEDULING ORDER: Joinder of Parties due by 12/12/2023. Amended Pleadings due by 12/12/2023. Fact Discovery completed by 5/16/2024. Dispositive Motions due by 11/7/2024. Answering Brief due 12/6/2024. Reply Brief due 12/20/2024. Joint Claim Construction Brief due by 12/20/2023. A Markman Hearing is set for 1/16/2024, at 9:00 AM in Courtroom 6A. A Pretrial Conference is set for 4/4/2025, at 9:00 AM in Courtroom 6A. A 5-day Jury Trial is set to start 4/21/2025, at 9:30 AM in Courtroom 6A (see Order for further details). Signed by Judge Richard G. Andrews on 7/10/2023. (nms) (Entered: 07/10/2023) (12) |
| Jul 10, 2023 | 27 | PROPOSED Scheduling Order, by Aventis Inc., Genzyme Corporation. (Wilks, David) Modified on 7/10/2023 (nms). (Entered: 07/10/2023) (12) |
| Jul 5, 2023 | 26 | ANSWER to 13 Answer to Complaint and Counterclaims, by Aventis Inc., Genzyme Corporation.(Wilks, David) Modified on 7/6/2023 (nms). (Entered: 07/05/2023) (9) |
| Jun 29, 2023 | N/A | Pro Hac Vice Attorney Amanda K. Antons, Judah Bellin, Katherine A. Helm, Pejmon Pashai, Sharon K. Gagliardi, Shyam Shanker, and Brian M. Goldberg for Aventis Inc. and Genzyme Corporation added for electronic noticing. Pursuant to Local Rule 83.5 (d)., Delaware counsel shall be the registered users of CM/ECF and shall be required to file all papers. (mpb) (Entered: 06/29/2023) (0) |
| Jun 23, 2023 | N/A | CORRECTING ENTRY: The docket text for the So Ordered entry filed on 6/22/2023, has been amended to reflect a ruling on D.I. 25 as well. (nms) (Entered: 06/23/2023) (0) |
| Jun 22, 2023 | N/A | SO ORDERED, re 24 MOTION for Pro Hac Vice Appearance of Attorney Pejmon Pashai, 21 MOTION for Pro Hac Vice Appearance of Attorney Daniel Roberts, 22 MOTION for Pro Hac Vice Appearance of Attorney Jonathan D.J. Loeb, 23 MOTION for Pro Hac Vice Appearance of Attorney Noah M. Leibowitz,and 25 MOTION for Pro Hac Vice Appearance of Attorney Shyam Shanker. Signed by Judge Richard G. Andrews on 6/22/2023. (nms) Modified on 6/23/2023 (nms). (Entered: 06/22/2023) (0) |
| Jun 22, 2023 | 25 | MOTION for Pro Hac Vice Appearance of Attorney Shyam Shanker - filed by Aventis Inc., Genzyme Corporation. (Wilks, David) (Entered: 06/22/2023) (2) |
| Jun 22, 2023 | 24 | MOTION for Pro Hac Vice Appearance of Attorney Pejmon Pashai - filed by Aventis Inc., Genzyme Corporation. (Wilks, David) (Entered: 06/22/2023) (2) |
| Jun 22, 2023 | 23 | MOTION for Pro Hac Vice Appearance of Attorney Noah M. Leibowitz - filed by Aventis Inc., Genzyme Corporation. (Wilks, David) (Entered: 06/22/2023) (2) |
| Jun 22, 2023 | 22 | MOTION for Pro Hac Vice Appearance of Attorney Jonathan D.J. Loeb - filed by Aventis Inc., Genzyme Corporation. (Wilks, David) (Entered: 06/22/2023) (2) |
| Jun 22, 2023 | 21 | MOTION for Pro Hac Vice Appearance of Attorney Daniel Roberts - filed by Aventis Inc., Genzyme Corporation. (Wilks, David) (Entered: 06/22/2023) (2) |
| Jun 15, 2023 | N/A | Pro Hac Vice Attorney Katherine A. Helm for Genzyme Corporation added for electronic noticing. Pursuant to Local Rule 83.5 (d)., Delaware counsel shall be the registered users of CM/ECF and shall be required to file all papers. (mkr) (Entered: 06/15/2023) (0) |
| Jun 15, 2023 | N/A | Pro Hac Vice Attorney M. David Weingarten, PhD, Jeffrey D. Smyth, John D. Livingstone, Cora R. Holt for Novartis Gene Therapies, Inc. and Novartis Pharmaceuticals Corporation added for electronic noticing. Pursuant to Local Rule 83.5 (d)., Delaware counsel shall be the registered users of CM/ECF and shall be required to file all papers. (mpb) (Entered: 06/15/2023) (0) |
| Jun 15, 2023 | 20 | Order Setting Rule 16(b) Conference: A Scheduling Conference is set for 7/12/2023, at 2:00 PM in Courtroom 6A (see Order for further details). Signed by Judge Richard G. Andrews on 6/15/2023. (nms) (Entered: 06/15/2023) (1) |
| Jun 14, 2023 | N/A | SO ORDERED, re 16 MOTION for Pro Hac Vice Appearance of Attorney Katherine, 19 MOTION for Pro Hac Vice Appearance of Attorney Judah Bellin, 15 MOTION for Pro Hac Vice Appearance of Attorney Martin J. Black, 18 MOTION for Pro Hac Vice Appearance of Attorney Amanda K. Antons, 14 MOTION for Pro Hac Vice Appearance of Attorney Sharon Gagliardi, 17 MOTION for Pro Hac Vice Appearance of Attorney Brian Goldberg. Signed by Judge Richard G. Andrews on 6/14/2023. (nms) (Entered: 06/14/2023) (0) |
| Jun 14, 2023 | 19 | MOTION for Pro Hac Vice Appearance of Attorney Judah Bellin - filed by Aventis Inc., Genzyme Corporation. (Wilks, David) (Entered: 06/14/2023) (2) |
| Jun 14, 2023 | 18 | MOTION for Pro Hac Vice Appearance of Attorney Amanda K. Antons - filed by Aventis Inc., Genzyme Corporation. (Wilks, David) (Entered: 06/14/2023) (2) |
| Jun 14, 2023 | 17 | MOTION for Pro Hac Vice Appearance of Attorney Brian Goldberg - filed by Aventis Inc., Genzyme Corporation. (Wilks, David) (Entered: 06/14/2023) (2) |
| Jun 14, 2023 | 16 | MOTION for Pro Hac Vice Appearance of Attorney Katherine A. Helm - filed by Aventis Inc., Genzyme Corporation. (Wilks, David) (Entered: 06/14/2023) (2) |
| Jun 14, 2023 | 15 | MOTION for Pro Hac Vice Appearance of Attorney Martin J. Black - filed by Aventis Inc., Genzyme Corporation. (Wilks, David) (Entered: 06/14/2023) (2) |
| Jun 14, 2023 | 14 | MOTION for Pro Hac Vice Appearance of Attorney Sharon Gagliardi - filed by Aventis Inc., Genzyme Corporation. (Wilks, David) (Entered: 06/14/2023) (2) |
| Jun 13, 2023 | N/A | SO ORDERED, re 12 MOTION for Pro Hac Vice Appearance of Attorney John Livingstone, M. David Weingarten, Ph.D., Cora Holt, and Jeffrey Smyth, filed by Novartis Pharmaceuticals Corporation, Novartis Gene Therapies, Inc.. Signed by Judge Richard G. Andrews on 6/13/2023. (nms) (Entered: 06/13/2023) (0) |
| Jun 13, 2023 | 13 | ANSWER to 1 Complaint, with Jury Trial Demanded , COUNTERCLAIM against Aventis Inc., Genzyme Corporation by Novartis Pharmaceuticals Corporation, Novartis Gene Therapies, Inc..(Silver, Daniel) (Entered: 06/13/2023) (30) |
| Jun 13, 2023 | 12 | MOTION for Pro Hac Vice Appearance of Attorney John Livingstone, M. David Weingarten, Ph.D., Cora Holt, and Jeffrey Smyth - filed by Novartis Gene Therapies, Inc., Novartis Pharmaceuticals Corporation. (Silver, Daniel) (Entered: 06/13/2023) (6) |
| Jun 6, 2023 | 11 | Disclosure Statement pursuant to Rule 7.1: identifying Corporate Parent Novartis AG for Novartis Pharmaceuticals Corporation filed by Novartis Pharmaceuticals Corporation. (Joyce, Alexandra) (Entered: 06/06/2023) (2) |
| Jun 6, 2023 | 10 | Disclosure Statement pursuant to Rule 7.1: identifying Corporate Parent Novartis AG for Novartis Gene Therapies, Inc. filed by Novartis Gene Therapies, Inc.. (Joyce, Alexandra) (Entered: 06/06/2023) (2) |
| Jun 6, 2023 | 9 | NOTICE of Appearance by Alexandra M. Joyce on behalf of Novartis Gene Therapies, Inc., Novartis Pharmaceuticals Corporation (Joyce, Alexandra) (Entered: 06/06/2023) (1) |
| Jun 6, 2023 | 8 | NOTICE of Appearance by Daniel M. Silver on behalf of Novartis Gene Therapies, Inc., Novartis Pharmaceuticals Corporation (Silver, Daniel) (Entered: 06/06/2023) (1) |
| May 24, 2023 | N/A | Case Assigned to Judge Richard G. Andrews. Please include the initials of the Judge (RGA) after the case number on all documents filed. (rjb) (Entered: 05/24/2023) (0) |
| May 24, 2023 | 7 | AFFIDAVIT of Service for Summons, Complaint and supporting documents served on Novartis Pharmaceuticals Corporation on May 23, 2023, filed by Aventis Inc., Genzyme Corporation. (Wilks, David) (Entered: 05/24/2023) (1) |
| May 24, 2023 | 6 | AFFIDAVIT of Service for Summons, Complaint and supporting documents served on Novartis Gene Therapies, Inc. on May 23, 2023, filed by Aventis Inc., Genzyme Corporation. (Wilks, David) (Entered: 05/24/2023) (1) |
| May 19, 2023 | 5 | Summons Issued as to Novartis Gene Therapies, Inc. and Novartis Pharmaceuticals Corporation on 5/19/2023. (Attachments: # 1 Summons Issued)(twk) (Entered: 05/19/2023) (0) |
| May 19, 2023 | 4 | Disclosure Statement pursuant to Rule 7.1: identifying Corporate Parent Sanofi for Aventis Inc., Genzyme Corporation filed by Aventis Inc., Genzyme Corporation. (twk) (Entered: 05/19/2023) (2) |
| May 19, 2023 | 3 | Report to the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 10,429,288. (twk) (Entered: 05/19/2023) (1) |
| May 19, 2023 | 2 | Notice, Consent and Referral forms re: U.S. Magistrate Judge jurisdiction. (twk) (Entered: 05/19/2023) (3) |
| May 19, 2023 | 1 | Complaint* (1) |
